淋巴结清扫范围与≤2cm肺癌亚肺叶切除肿瘤学疗效相关
该研究基于SEER-Medicare数据库,纳入2757例肺叶切除和1229例亚肺叶切除的I期≤2cm非小细胞肺癌患者,经倾向匹配后比较生存。亚肺叶切除组未清扫淋巴结比例更高(46.9% vs 6.4%),总生存和癌症特异性生存更差;但当清扫≥9枚淋巴结时,两组生存无差异。
要点
- 亚肺叶切除患者未清扫淋巴结比例显著高于肺叶切除(46.9% vs 6.4%)。
- 亚肺叶切除与更差的总生存(HR 1.48)和癌症特异性生存(HR 2.06)相关。
- 清扫≥9枚淋巴结时,亚肺叶切除与肺叶切除的生存无显著差异。
核心结论
- 亚肺叶切除导致淋巴结清扫数量更少,并与较差的生存相关。
- 更广泛的淋巴结清扫可能使亚肺叶切除与肺叶切除的匹配患者获得等效生存。
研究设计与样本
- 基于SEER-Medicare数据库的回顾性队列研究,纳入年龄≥66岁、I期、肿瘤≤2cm的非小细胞肺癌患者。
- 共纳入2757例肺叶切除和1229例亚肺叶切除,经倾向匹配后每组1124例。
主要发现
- 亚肺叶切除组无淋巴结采样比例为46.9%,肺叶切除组为6.4%(P < .001)。
- 倾向匹配后,亚肺叶切除的总生存HR为1.48(95%CI 1.29-1.69),癌症特异性生存HR为2.06(95%CI 1.41-3.02)。
- 至少清扫1枚淋巴结的匹配队列(每组567例)中,亚肺叶切除的总生存HR为1.38(95%CI 1.12-1.69),癌症特异性生存HR为1.58(95%CI 0.97-2.57)。
- 清扫≥9枚淋巴结的匹配队列(每组103例)中,总生存HR为0.84(95%CI 0.50-1.39),癌症特异性生存HR为1.10(95%CI 0.35-3.41)。
临床怎么用
- 对于≤2cm的I期非小细胞肺癌,选择亚肺叶切除时应重视淋巴结清扫,避免遗漏采样。
- 清扫至少9枚淋巴结可能缩小亚肺叶切除与肺叶切除之间的生存差距。
局限性
- 回顾性数据库研究,可能存在选择偏倚和未测量混杂因素。
- 清扫≥9枚淋巴结的匹配队列样本量较小(每组103例),结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sublobar resection (SLR) is an alternative to lobectomy for early non-small cell lung cancer. Comparative effectiveness of these 2 approaches might be modified by the extent of lymph node dissection. METHODS: We utilized the Surveillance, Epidemiology, and End Results Program-Medicare dataset to identify patients with stage I non-small cell lung cancer aged 66 years or older with tumor size ≤2 cm. We compared patient characteristics with t tests for continuous variables and χ2 tests for categorical variables. Kaplan-Meier curves were constructed to determine overall survival (OS) and cancer-specific survival (CSS). We evaluated OS and CSS among propensity-matched cohorts undergoing lobectomy versus SLR, particularly as it related to extent of lymphadenectomy. RESULTS: Among 2757 lobectomies and 1229 SLR procedures performed for stage I tumors ≤2 cm, we propensity-matched 1124 patients from each group. Patients undergoing SLR were more likely to have no lymph nodes sampled (46.9% vs 6.4%; P < .001). OS (hazard ratio [HR], 1.48; 95% confidence interval [CI], 1.29-1.69) and CSS (HR, 2.06; 95% CI, 1.41-3.02) were worse following SLR. When propensity-matched cohorts of patients with at least 1 lymph node removed (n = 567 each group) were examined, the HRs for survival for SLR decreased (OS HR, 1.38; 95% CI, 1.12-1.69; CSS HR, 1.58; 95% CI, 0.97-2.57). Finally, when cohorts were propensity matched for ≥9 lymph nodes examined (n = 103 each group), there was no difference in OS (HR, 0.84; 95% CI, 0.50-1.39) or CSS (HR, 1.10; 95% CI, 0.35-3.41). CONCLUSIONS: SLR leads to fewer lymph node removed and is associated with inferior survival compared with lobectomy. A more extensive lymphadenectomy may be associated with equivalent survival between matched patients undergoing SLR and lobectomy.
引用
- Stiles BM, Mao J, Harrison S, et al. Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer ≤2 cm. J Thorac Cardiovasc Surg. 2019. PMID: 30954298. doi:10.1016/j.jtcvs.2019.01.136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。